- About Us
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences,Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(OTC Bulletin Board: BFNH.OB), announced that it exceeded its 2006 goal for
shipping up to 20 of its cutting-edge Nano eNabler(TM) molecular printers
to prestigious institutions across the globe. BioForce exceeded its goal by
two units by year end. These pilot placements of the Company's patented
Nano eNabler device at centers of research excellence, allow the
entrepreneurial researchers at those centers to act as "early adopters" of
BioForce's practical tools and technologies.
"With the shipment of these 22 Nano eNabler molecular printers," says
BioForce Product Manager Michael Lynch, "BioForce is now essentially
partnering with an impressive group of innovators working in the micro and
nanotechnology fields. Several groups have already expressed a desire to
seek funds to convert their placement into a purchase."
Kerry Frey, BioForce's chief operating officer, says, "BioForce
Nanosciences is positioned between two very exciting markets-nanotechnology
and the life sciences. We strongly believe our Nano eNabler system will
change how research is conducted in laboratories across the world." He
explains that the ease of use and practicality provided by the Nano eNabler
system, establish a path from laboratory to industry.
Institutions where recent placements have taken place:
* University of California, Cal-it2, Irvine, CA
* Cornell University, NanoBioTechnology Center, Ithaca, NY
* ETH Zurich, Zurich, Switzerland
* Georgia Institute of Technology, Microelectronics Research Center,
* Stanford University, James H. Clark Center, Stanford, CA
About BioForce Nanosciences
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce
Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). BioForce
Nanosciences is a unique company entering into commercialization with over
a decade of research and accomplishment in the field of bionanotechnology.
BioForce has demonstrated the ability to take a product from concept to
commercial sale. For more information, visit http://www.bioforcenano.com.
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
For more information, please click here
Copyright © PR NewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017
Next-gen steel under the microscope March 18th, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016